ADA and neoplasm: These findings indicate that seven tumor antigens (ADA, FYN, HDC, NFKBIZ, RASSF4, SLC6A3, and UPP1) have potential immune-stimulating effects and can be processed and presented by antigen-presenting cells (APC) to induce tumor responses, and are hopeful candidates for developing anti-PRAD mRNA vaccine.